Management of Active Crohn Disease

被引:97
作者
Cheifetz, Adam S. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2013年 / 309卷 / 20期
关键词
INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; ACTIVITY INDEX; MAINTENANCE INFLIXIMAB; MONOCLONAL-ANTIBODY; HUMANIZED ANTIBODY; BIOLOGICAL THERAPY; AMERICAN-COLLEGE;
D O I
10.1001/jama.2013.4466
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance: Treatment of Crohn disease is rapidly evolving, with the induction of novel biologic therapies and newer, often more intensive treatment approaches. Knowing how to treat individual patients in this quickly changing milieu can be a challenge. Objective: To review the diagnosis and management of moderate to severe Crohn disease, with a focus on newer treatments and goals of care. Evidence Review: MEDLINE was searched from 2000 to 2011. Additional citations were procured from references of select research and review articles. Evidence was graded using the American Heart Association level-of-evidence guidelines. Results: Although mesalamines are still often used to treat Crohn disease, the evidence for their efficacy is lacking. Corticosteroids can be effectively used to induce remission in moderate to severe Crohn disease, but they do not maintain remission. The mainstays of treatment are immunomodulators and biologics, particularly anti-tumor necrosis factor. Conclusion and Relevance: Immunomodulators and biologics are now the preferred treatment options for Crohn disease. ©2013 American Medical Association. All rights reserved.
引用
收藏
页码:2150 / 2158
页数:9
相关论文
共 79 条
  • [1] Ananthakrishnan AN, 2013, INFLAMM BOWEL DIS, V19, P37, DOI [10.1097/MIB.0b013e3182902ad9, 10.1002/ibd.22951]
  • [2] Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
    Baert, Filip
    Moortgat, Liesbeth
    Van Assche, Gert
    Caenepeel, Philip
    Vergauwe, Philippe
    De Vos, Martine
    Stokkers, Pieter
    Hommes, Daniel
    Rutgeerts, Paul
    Vermeire, Severine
    D'Haens, Geert
    [J]. GASTROENTEROLOGY, 2010, 138 (02) : 463 - 468
  • [3] Predictors of Crohn's disease
    Beaugerie, L
    Seksik, P
    Nion-Larmurier, I
    Gendre, JP
    Cosnes, J
    [J]. GASTROENTEROLOGY, 2006, 130 (03) : 650 - 656
  • [4] Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Beaugerie, Laurent
    Brousse, Nicole
    Bouvier, Anne Marie
    Colombel, Jean Frederic
    Lemann, Marc
    Cosnes, Jacques
    Hebuterne, Xavier
    Cortot, Antoine
    Bouhnik, Yoram
    Gendre, Jean Pierre
    Simon, Tabassome
    Maynadie, Marc
    Hermine, Olivier
    Faivre, Jean
    Carrat, Fabrice
    [J]. LANCET, 2009, 374 (9701) : 1617 - 1625
  • [5] Traditional corticosteroids for induction of remission in Crohn's disease
    Benchimol, E., I
    Seow, C. H.
    Steinhart, A. H.
    Griffiths, A. M.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [6] BEST WR, 1976, GASTROENTEROLOGY, V70, P439
  • [7] European evidence-based Consensus on the management of ulcerative colitis: Special situations (Publication with Expression of Concern)
    Biancone, Livia
    Michetti, Pierre
    Travis, Simon
    Escher, Johanna C.
    Moser, Gabriele
    Forbes, Alastair
    Hoffmann, Joerg C.
    Dignass, Axel
    Gionchetti, Paolo
    Jantschek, Guenter
    Kiesslich, Ralf
    Kolacek, Sanja
    Mitchell, Rod
    Panes, Julian
    Soderholm, Johan
    Vucelic, Boris
    Stange, Eduard
    [J]. JOURNAL OF CROHNS & COLITIS, 2008, 2 (01) : 63 - 92
  • [8] Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data
    Bodger, K.
    Kikuchi, T.
    Hughes, D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 265 - 274
  • [9] Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease
    Canavan, C
    Abrams, KR
    Mayberry, J
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) : 1097 - 1104
  • [10] The incidence and management of infusion reactions to infliximab: A large center experience
    Cheifetz, A
    Smedley, M
    Martin, S
    Reiter, M
    Leone, G
    Mayer, L
    Plevy, S
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (06) : 1315 - 1324